Valuation: Armata Pharmaceuticals, Inc.

Market Cap 170M 147M 138M 125M 235M 16.18B 239M 1.61B 631M 8.11B 636M 623M 27.03B P/E 2026 *
-2.01x
P/E 2027 * -3.26x
Enterprise Value 170M 147M 138M 125M 235M 16.18B 239M 1.61B 631M 8.11B 636M 623M 27.03B EV / Sales 2026 *
32.6x
EV / Sales 2027 * 61.7x
Free-Float
32.36%
Yield 2026 *
-
Yield 2027 * -
1 day-5.39%
1 week-3.18%
Current month+0.44%
1 month+14.29%
3 months-43.35%
6 months-44.05%
Current year-27.39%
1 week 3.96
Extreme 3.96
5.04
1 month 3.8
Extreme 3.8
5.7
Current year 3.48
Extreme 3.48
14.98
1 year 2.4
Extreme 2.4
16.34
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 11/07/2023
Director of Finance/CFO 42 16/08/2024
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 09/05/2019
Director/Board Member 66 12/02/2020
Director/Board Member 51 12/02/2020
Date Insider Type Main position Quantity % Market Cap.
7/10/26 A Tax

Chief Executive Officer

-14,041 0.0382%
4/24/26 A Free

Director

51,280 0.1400%
3/9/26 A Free

Director

25,640 0.0704%
Change 5-day change 1-year change 3-year change Capi.($)
-5.39%-3.18%+78.82%+6.05% 170M
-1.90%+2.85%+62.82%+104.13% 70.07B
-3.21%-4.32%+31.85%+57.27% 52.87B
-2.05%-5.61%-3.18%+449.71% 27.02B
-1.27%-1.57%+45.90%+8.25% 23.61B
+1.05%-0.62%-18.00%-11.93% 23.38B
+3.81%+20.97%+266.37%+531.28% 19.43B
+0.10%+1.40%+35.36%-19.94% 18.75B
-0.95%-3.52%+19.93%+594.00% 15.85B
+1.24%-5.23%+33.75%+137.66% 12.7B
Average -0.86%+2.01%+55.36%+185.65% 26.39B
Weighted average by Cap. -1.09%+0.56%+50.25%+164.89%

Financials

2026 *2027 *
Net sales 5.2M 4.5M 4.23M 3.84M 7.21M 496M 7.34M 49.48M 19.34M 249M 19.52M 19.1M 829M 2.75M 2.38M 2.24M 2.03M 3.82M 262M 3.88M 26.17M 10.23M 132M 10.32M 10.1M 438M
Net income -83.8M -72.45M -68.16M -61.93M -116M -8B -118M -797M -312M -4.01B -315M -308M -13.36B -68.55M -59.27M -55.76M -50.66M -95.1M -6.54B -96.77M -652M -255M -3.28B -257M -252M -10.93B
Net Debt - -
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
14/08/26 $4.560 -5.39% 110,611
13/08/26 $4.820 +11.83% 169,020
12/08/26 $4.310 +1.41% 126,489
11/08/26 $4.250 -7.61% 231,122
10/08/26 $4.600 -2.34% 81,560
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.560USD
Average target price
17.50USD
Spread / Average Target
+283.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARMP Stock